Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
MTRR	4552	HYDROXOCOBALAMIN	CHEMBL2103737	other	DrugBank	17139284, 17016423
MTRR	4552	TEGAFUR	CHEMBL20883		PharmGKB
MTRR	4552	CYANOCOBALAMIN	CHEMBL2110563	cofactor	DrugBank	16268464, 15979034, 15612980, 17024475, 17611986
MTRR	4552	METHIONINE	CHEMBL42336	product of	DrugBank	17101561, 17369066, 17079868
MTRR	4552	VITAMIN B12	CHEMBL2375172		NCI	12807760

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
MTRR	rs1801394	A	methotrexate	efficacy	yes	The A allele was independently associated with worse response using two distinct measures of response 1) the difference in Disease Activity Score 28 between baseline and 6 months later (deltaDAS28) and 2) the European League Against Rheumatism (EULAR) criteria. For DAS28, each A allele corresponded to 0.14 deltaDAS28 units in an additive model vs the G allele (indicating worse response assoc. with A allele). Using EULAR criteria the A allele also had an increased OR=1.39 for non-response (95% CI 1.11–1.75).	Allele A is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.	29743634	1449557869
MTRR	rs1801394	G	methotrexate	toxicity	no	Discontinuation due to adverse effects.	Allele G is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele A.	27217051	1449164948
MTRR	rs1801394	AG + GG	methotrexate	efficacy	yes	Authors say this variant is associated with response in dominant model (minor allele/minor allele + minor/major vs major major and describe variant as A>G).	Genotypes AG + GG is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype AA.	29589488	1449270277
MTRR	rs162040	A	methotrexate	efficacy	no		Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.	29743634	1449558033